Given the grim prognosis of patients with high-grade gliomas, it is imperative to consider quality of life when evaluating treatment options. We therefore sought to determine the efficacy and toxicity ...

A trial of Incyte's Pemazyre in patients with FGFR-altered brain cancer did not meet its primary endpoint but had encouraging secondary outcomes.

Malignant gliomas account for approximately 70% of the 22,500 new cases of malignant primary brain tumors that are diagnosed in adults in the United States each year. 1–3 Although relatively ...

reduce neurotoxicity caused by excess glutamate release and help to avoid the occurrence of seizures and neurological dysfunction that are frequently associated with gliomas. Next, the team ...

Gliomas are the most common malignant primary brain tumor in adults and are categorized by the World Health Organization (WHO) into distinct tumor subtypes and tumor grades according to a ...

In the largest ever study of its kind, an analysis of entire tumor genomes has provided the most complete picture yet of an ...

Real-world experience with vorasidenib in IDH-mutant gliomas: Tolerability, adverse events, and access in patients who did not meet INDIGO trial eligibility criteria. This is an ASCO Meeting Abstract ...

In the largest-ever study of its kind, an analysis of entire tumor genomes has provided the most complete picture yet of an ...

For patients with diffuse gliomas, tumor-related epilepsy (TRE) is not a strong prognostic factor, according to a study ...

Optic glioma is also referred to as an optic pathway glioma. Optic gliomas stem from glial cells in your brain that function to support and nourish your brain’s neurons. They grow near your eye ...